The global blood screening market was valued at USD 2.31 billion in 2018 and is anticipated to grow to USD 6.63 billion by 2032, reflecting a compound annual growth rate (CAGR) of 7.9% over the forecast period. In 2018, North America led the global market, accounting for 41.86% of the total share.

The Blood Screening Market encompasses a range of diagnostic procedures used to test donated blood for infections, diseases, and other health conditions before it is used for transfusions or other medical purposes. This market plays a critical role in ensuring the safety of blood supplies and preventing the transmission of infections such as HIV, hepatitis B and C, syphilis, and other transfusion-transmissible diseases. Driven by increasing demand for safe blood, rising awareness about blood-related disorders, and advancements in screening technologies such as nucleic acid testing and immunoassays, the Blood Screening Market continues to expand. Government initiatives, stringent regulations, and the growing need for early disease detection further contribute to the growth of this essential healthcare sector.

Continue reading for more details:

https://www.fortunebusinessinsights.com/blood-screening-market-102552

Market Segmentation

• By Technology: The Blood Screening Market is divided into immunoassays, nucleic acid testing (NAT), serological tests, and rapid diagnostic tests.

• By Application: Screening for infectious diseases, cancer biomarkers, genetic disorders, and anemia contribute diverse segments within the Blood Screening Market.

• By End‑User: Hospital labs, diagnostic centers, blood banks, and reference laboratories each capture distinct portions of the Blood Screening Market.

• By Sample Type: The Blood Screening Market includes whole blood, serum, plasma, and point-of-care sample formats.

List Of Key Companies Profiled:

• Bio-Rad Laboratories, Inc.

• Grifols, S.A.

• Hoffmann-La Roche

• Ortho Clinical Diagnostics

• BD

• DiaSorin S.p.A.

• Thermo Fisher Scientific Inc.

• Abbott

• QUOTIENT

• Other Players

Market Growth

• The Blood Screening Market has experienced strong upward momentum due to increasing demand for early disease detection and blood safety.

• Rising prevalence of infectious diseases and chronic conditions is driving rapid expansion of the Blood Screening Market.

• Technological innovations such as automated immunoassays, molecular diagnostics, and high-throughput screening are fueling the Blood Screening Market growth.

• Expansion in blood transfusion services and donor screening programs continues to propel the Blood Screening Market forward.

Restraining Factors

• High costs of advanced screening technologies and equipment are significant restraints on the Blood Screening Market.

• Regulatory complexities and varying approval timelines hinder product launches within the Blood Screening Market.

• Limited infrastructure in low- and middle-income countries restricts accessibility to blood screening solutions, impacting the Blood Screening Market.

• Concerns over data privacy and accuracy of rapid point-of-care tests pose challenges within the Blood Screening Market.

Regional Analysis

• North America: Dominates the Blood Screening Market due to advanced healthcare infrastructure and stringent safety regulations.

• Europe: Growth in the Blood Screening Market is driven by nationwide donor screening programs and adoption of molecular testing.

• Asia-Pacific: Witnessing rapid growth in the Blood Screening Market, powered by rising healthcare investment and increasing disease burden.

• Latin America & MEA: The Blood Screening Market is expanding steadily, though hampered by budget constraints and limited regulatory harmonization.

Contact us:

Fortune Business Insights™ Pvt.

Phone: USA: +1 833 909 2966 (Toll-Free),

United Kingdom: +44 808 502 0280 (Toll-Free)

APAC: +91 744 740 1245

Email: sales@fortunebusinessinsights.com